What is the BridgeBio Pharma Inc (BBIO) price today?

The price of BridgeBio Pharma Inc (BBIO) today is $72.17. This value reflects the latest market rate available on Pluang. Check the asset page for additional details such as 24-hour change, market trends, and trading volume.

What are the trading hours of US Stocks?

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.

Do I get a dividend from investing in US Stocks?

Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.

What is the fee for each transaction?

Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/Explore/US Market Price/Stocks/BBIO

Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today

Overview Financials Technicals Analysis Corp Action About

24H

YTD

Aura AI Summary

BridgeBio Pharma (BBIO) trades at $71.93, down 1.67% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported revenue growth to $502M in 2025 but remains unprofitable with a net income margin of -144.39%. Recent news highlights regulatory progress, including an NDA submission for BBP-418 and positive long-term data for acoramidis, driving investor optimism despite persistent cash burn from operations.

The outlook hinges on successful drug approvals and commercialization to offset high R&D costs. Analyst consensus is strongly bullish with a $97.44 price target, but risks include reliance on pipeline success, substantial debt, and ongoing losses. Upside potential exists if clinical milestones are met, but volatility may persist until profitability improves.

Read full analysis

Key Stats

Market Cap
$14.01B
Sector
Health
3M Drawdown
-20.25%
Enterprise Value
$15.29B
Dividend Yield
-
Trading Activity
21% Buy | 79% Sell
Typical Hold Time
56 days

$72.17

52W Low: $30.14

08 Apr 2025

52W High: $79.91

22 Jan 2026

BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $14.01B, with an enterprise value of $15.29B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $30.14 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -20.25%, reflecting recent price volatility. BridgeBio Pharma Inc offers a dividend yield of -. On average, investors hold BridgeBio Pharma Inc for approximately 56 days, indicating typical investor behavior on the platform.

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Technical Indicators

Overall Summary

Bearish (5)Neutral (10)Bullish (12)

News

Benzinga2 mon ago

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

Benzinga3 mon ago

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Globe Newswire5 mon ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Globe Newswire5 mon ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Globe Newswire5 mon ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

People also bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

Market Cap
$14.01B
Sector
Health
3M Drawdown
-20.25%
Enterprise Value
$15.29B
Dividend Yield
-
Trading Activity
21% Buy | 79% Sell
Typical Hold Time
56 days

$72.17

52W Low: $30.14

08 Apr 2025

52W High: $79.91

22 Jan 2026

Let’s invest in this asset by signing up or download!

Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today

Aura AI Summary

Key Stats

About BridgeBio Pharma Inc

People also bought

Key Stats

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store